Tilray Brands ($TLRY): Can BrewDog Growth Become Operating Cash?

01 Scenarios — can the larger platform fund itself?

What Would Falsify This Reading

• Operating cash catches up. Sustained cash generation after working-capital needs and asset maintenance would weaken the view that external financing remains central.
• Organic beverage performance becomes transparent. Stable sales and stronger gross profit in the pre-acquisition portfolio would challenge the interpretation that purchased revenue is doing most of the visible work.
• International cannabis volume improves economics. Better pricing, collections and contribution after compliance and distribution costs would establish more than a shipment-growth story.
• Capital discipline improves per-share outcomes. Lower financing needs alongside controlled stock issuance would show that the enlarged platform can benefit existing owners without continually expanding the denominator.

02 A diversified group requires a different revenue lens

Tilray reports beverage, cannabis, pharmaceutical distribution and wellness as separate segments, with consolidated statements prepared in US dollars under US GAAP. Its annual reporting period ends in May rather than December; treating calendar-year news as if it belonged to the same fiscal quarter can shift an acquisition or operating event into the wrong comparison. The segment distinction also prevents the entire company from being valued or described as a Canadian cannabis producer. Annual report

For the fiscal year ended May 31, 2026, net revenue was US$915.454 million, against US$821.309 million a year earlier; the same annual report records beverage revenue of US$253.976 million, cannabis revenue of US$268.342 million, distribution revenue of US$327.244 million and wellness revenue of US$65.892 million. Annual report, Notes 21 and 29 Distribution is the largest revenue segment in that reporting period, but its role is primarily pharmaceutical purchasing and resale. It does not imply that the same amount represents medical-cannabis sales.

Gross profit tells a different story from the ranking by sales. For the year ended May 31, 2026, segment gross profit was US$91.233 million for beverages, US$107.086 million for cannabis, US$40.655 million for distribution and US$21.467 million for wellness, according to the annual segment reconciliation. Annual report, Note 29 Cannabis therefore contributed more gross profit than distribution despite producing less revenue. A change in mix toward a lower-margin business can enlarge the headline top line without a proportionate improvement in the resources available to cover corporate expenses.

The group also spans different commercial systems. Canadian recreational cannabis moves through regulated provincial and retail channels; medical cannabis requires compliant supply and patient access; pharmaceuticals depend on inventory availability and customer credit; craft beer requires distributor relationships, shelf space and brand spending. Hospitality adds venues, staffing and lease commitments. These systems can share logistics or commercial contacts, but they do not necessarily share margins, seasonality or regulatory permissions. Annual report, Business and segment reporting

Consolidated growth must consequently be unpacked into volume, price, currency and acquired scope. In the fiscal year ended May 31, 2026, Tilray reports constant-currency revenue of US$883.904 million, compared with US$821.309 million in the prior year; this represents an 8% reported constant-currency growth rate rather than the 11% increase in reported US-dollar revenue. Annual report, MD&A Constant currency removes an exchange-rate effect, but it does not remove acquisitions. Calling that comparison organic would introduce a second adjustment that the calculation does not make.

The practical implication is to ask which business earns each dollar of gross profit and what additional costs and capital accompany it. Diversification can reduce reliance on a single regulatory catalyst. It can also complicate the evaluation of returns when acquisitions and financing transactions arrive faster than a stable record of operating cash.

03 The annual improvement and the quarter before BrewDog

The fiscal-year income statement contains a genuine improvement in gross profit, alongside a much larger change in accounting charges. For the year ended May 31, 2026, gross profit increased to US$260.441 million from US$240.570 million, while the annual operating loss narrowed to US$63.027 million from US$2,282.705 million. Annual report, consolidated statements of loss Those changes are not evidence of the same underlying economic movement.

The prior fiscal year included US$2,096.139 million of impairment charges on goodwill and intangible assets; the fiscal year ended May 31, 2026 contained no such charge, according to the annual income statement. Annual report Removing a very large impairment from the year-on-year comparison makes losses look dramatically smaller without creating cash in the current year. It also does not establish that the original acquisition spending has earned a satisfactory return.

For the year ended May 31, 2026, consolidated net loss was US$105.158 million, while the loss attributable to Tilray stockholders was US$121.397 million; the difference reflects US$16.239 million of income attributable to non-controlling interests. Annual report The distinction matters when connecting the group income statement to earnings per share. Consolidated loss is not the exact numerator belonging to common shareholders.

Adjusted EBITDA for the year ended May 31, 2026 was US$61.139 million, compared with US$55.035 million in the prior year, in the July 28 results reconciliation. Annual results The measure adds back items including interest, tax, amortization, stock compensation, restructuring and transaction costs. It helps describe operating trends under management’s definition, but it is neither GAAP profit nor the cash left after collecting sales, paying suppliers and investing in assets.

The latest standalone quarterly filing covers February 28, 2026, before the BrewDog transactions entered consolidation; that quarter’s revenue was US$206.732 million, and its operating cash outflow was US$21.942 million. Latest Form 10-Q The subsequent May-quarter results show revenue of US$281.714 million and an operating cash outflow of US$37.324 million for the three months ended May 31, 2026. Annual results The larger quarter therefore coincided with a larger cash outflow. Scope and seasonality complicate the comparison, but neither complication converts the outflow into a cash-generation success.

The May quarter did deliver higher gross profit: US$90.521 million in the three months ended May 31, 2026, against US$67.633 million in the corresponding prior-year quarter. Annual results The right follow-through is to examine whether that contribution covers the enlarged cost base and becomes cash over subsequent reporting periods. A sequential sales jump by itself does not show that legacy operations accelerated, because BrewDog was absent from the February reporting perimeter.

04 International medical cannabis and pharmaceutical distribution

International cannabis offers growth outside Canada’s mature recreational market, but exporting additional product does not eliminate pricing and permit risks. For the fiscal year ended May 31, 2026, international cannabis revenue was US$84.910 million, compared with US$63.356 million in the prior year; in constant currency the annual figure was US$78.899 million, according to the MD&A. Annual report Currency therefore supported part of the reported increase.

The annual MD&A attributes growth to markets including Germany, Poland and the United Kingdom, while describing price compression and the timing of import and export permissions. For the year ended May 31, 2026, management identifies a US$21.1 million adverse pricing effect on international cannabis revenue, offset by higher activity and other factors. Annual report, international cannabis discussion That amount explains why greater volume and stronger reported revenue can coexist with pressure on the economics of individual shipments.

A compliant cultivation and distribution chain may help Tilray serve regulated markets, yet each link has a separate commercial test. Production must meet the relevant quality standard; permissions must allow the shipment; the local distributor or pharmacy must accept it; and the receivable must be collected. Inventory at a cultivation site is not a completed patient sale. A supply agreement or distribution presence is also not a guaranteed minimum revenue stream unless the relevant contract provides one.

CC Pharma belongs in this discussion without being confused with international cannabis. For the year ended May 31, 2026, the distribution segment produced US$327.244 million of revenue and US$40.655 million of gross profit, compared with US$271.228 million and US$29.332 million respectively a year earlier. Annual report, Note 29 Its broader pharmaceutical operations can provide relationships and infrastructure, but their sales are not international cannabis sales and do not represent cannabis exposure.

Tilray acquired Lyphe on April 15, 2026 for total consideration of US$3.074 million, comprising US$2.795 million in shares and US$0.279 million in cash; the annual acquisition note identifies 398,666 shares issued and describes a UK medical clinic and digital-pharmacy platform. Annual report, Note 9 This adds a patient-access layer to supply and distribution. The commercial logic is closer contact with the route to prescription and fulfillment, not proof that every consultation becomes recurring product revenue.

Tilray’s August 20, 2026 announcement reports approximately 275 metric tonnes of annual global cultivation capacity and presents Quebec EU-GMP certification as an objective within the following twelve months, rather than a certificate already issued. Capacity announcement Capacity is not actual annual output, utilization or contracted demand. The useful future evidence is saleable production absorbed at acceptable pricing, supported by permissions and collection quality.

The same distinction applies to new digital healthcare capabilities. The June 29, 2026 HelloMD announcement describes planned acquisition of Canadian assets following formal court approval and does not disclose financial terms. HelloMD announcement Later issuer descriptions include the platform within the medical-access strategy, but undisclosed pricing and future patient benefits should not be replaced with invented economics.

05 Canadian cannabis — pricing, excise and product mix

Canadian cannabis remains a substantial business, but its medical, recreational and wholesale channels behave differently. For the year ended May 31, 2026, the annual channel table records Canadian medical revenue of US$23.726 million, recreational revenue of US$236.352 million and wholesale revenue of US$7.318 million, before the segment’s US$83.964 million excise deduction; international revenue completes the reconciliation to net cannabis sales. Annual report, Note 29 Adding gross channel amounts and comparing them with net consolidated revenue would exaggerate cannabis’s share of the group.

The medical line declined from US$24.998 million in the year ended May 31, 2025 to US$23.726 million in the year ended May 31, 2026. Annual report Management describes competitive conditions, patient attrition and reimbursement changes rather than presenting every medical market as a uniformly growing opportunity. Patient-access investments can strengthen the route to market, but they do not cancel a reduction in reimbursement or a patient’s ability to switch providers.

Veterans Affairs Canada’s maximum reimbursement rate changed from C$8.50 to C$6.00 per gram effective April 1, 2026, as the agency’s revised-policy explanation states. VAC policy Tilray’s annual MD&A attributes an approximately US$0.8 million fiscal-year revenue effect to this change for the year ended May 31, 2026. Annual report The reimbursement ceiling is a Canadian policy parameter, not a US contract, and the company-specific revenue effect is management’s explanation of that reporting period.

Recreational cannabis generated US$236.352 million of annual gross channel revenue in the year ended May 31, 2026, against US$224.048 million a year earlier, while wholesale revenue fell to US$7.318 million from US$18.207 million. Annual report A shift away from lower-priority wholesale activity may be deliberate, but the reader needs to examine the quality and cost of the replacement sales. Higher branded revenue is more persuasive when it supports margin and collection rather than only volume.

The May quarter highlights that growth was not evenly distributed. Canadian recreational revenue was US$57.267 million for the three months ended May 31, 2026, compared with US$58.421 million in the prior-year quarter; international revenue rose to US$27.242 million from US$22.365 million in the same comparison. Annual results The segment’s aggregate result can therefore conceal a weaker domestic recreational line.

Product mix, promotions and retail bargaining power remain relevant. The annual MD&A describes growth in pre-rolls, weaker flower performance and pricing pressure; its market-share observations rely on named third-party datasets with stated coverage limits. Annual report These are useful company disclosures, but they do not justify turning a temporary ranking into an unqualified permanent leadership claim.

An expanded cultivation footprint creates a further capital question. If more product waits for export permissions or replaces profitable domestic sales, physical capacity can rise faster than realized contribution. The falsification test is not a larger cultivation headline. It is stable pricing and a repeatable gross-profit contribution after inventory, compliance and sales costs, with a visible route from shipment to collected cash.

06 What Tilray purchased in BrewDog

BrewDog changed the beverage perimeter through selected asset and business purchases, not a simple purchase of every obligation associated with the former group. The annual acquisition note places the UK transaction on March 2, 2026, the Australian transaction on March 9, additional UK pubs on March 23 and the US accounting acquisition date on April 1. Annual report, Note 9 The legal assets acquired and the date control was obtained determine what enters consolidation.

The UK initial cash consideration was £33.0 million, translated to US$44.220 million in the annual acquisition table; the additional UK pub purchase was US$0.560 million, and the US transaction was US$9.293 million, according to the note for the fiscal year ended May 31, 2026. Annual report These latest annual figures supersede rounded transaction descriptions used in earlier quarterly announcements. The Australian consideration was nominal, rather than proof that the acquired operation had no future operating obligations.

Total BrewDog cash consideration in the annual acquisition table was US$54.073 million for the transactions completed during the fiscal year ended May 31, 2026. Annual report The price paid is only part of the commitment. The acquired assets included lease rights and corresponding liabilities, inventory and working-capital balances. A low purchase multiple or an administration sale can transfer an operation cheaply while leaving significant needs for staffing, maintenance, promotion and cash collection.

The annual purchase-price allocation records US$155.557 million of assumed liabilities across the BrewDog acquisitions, including operating and finance leases, as of their respective acquisition dates in March and April 2026. Annual report, Note 9 This is not all conventional bank debt, and it does not represent an immediate cash payment on top of the purchase price. It does show why a cash-only headline understates the operating commitments behind the transaction.

The annual unaudited pro-forma disclosure estimates US$190.198 million of additional revenue and US$41.428 million of additional net loss if the acquired BrewDog asset groups had been owned from June 1, 2025, for the year ended May 31, 2026. Annual report Those are hypothetical reporting-perimeter figures, not actual revenue or loss newly generated in a future year. They demonstrate that a larger historical platform would also have contained losses requiring improvement.

Tilray’s July 28, 2026 results release describes a beverage platform of approximately US$500 million on a pro-forma basis; actual beverage revenue for the year ended May 31, 2026 was US$253.976 million. Annual results The pro-forma ambition and the reported segment are different objects. Neither should be silently substituted for the other.

The integration opportunity is to combine recognized brands, production and routes to market more efficiently. The integration risk is that an acquired network brings complexity and fixed commitments before the combined portfolio earns enough cash to cover them. Subsequent evidence must show how acquired sales, margins, working capital and lease costs behave together, rather than treating ownership itself as a completed turnaround.

07 Beverage execution beyond the acquired top line

The pre-existing beverage business needs its own assessment. For the year ended May 31, 2026, beverage revenue increased to US$253.976 million from US$240.595 million, while beverage gross profit declined to US$91.233 million from US$93.004 million and the reported gross margin fell to 36% from 39%. Annual report, MD&A and Note 29 A larger segment produced less gross profit in this annual comparison, despite the added BrewDog business.

The annual MD&A identifies approximately US$51.1 million of additional BrewDog revenue during the year ended May 31, 2026. Annual report As an illustrative calculation using those disclosed inputs, subtracting that contribution from total beverage sales gives approximately US$202.9 million for the remaining perimeter; compared with the prior-year US$240.595 million total, the difference is approximately US$37.7 million. Annual report; Merlintrader calculation This is a rough scope comparison, not a company-reported organic growth rate, because other perimeter and portfolio changes also affect comparability.

Management links part of the legacy weakness to selected brand and SKU reductions, distribution changes and the anticipated hemp-derived beverage restrictions. The annual narrative presents these actions as efforts to improve profitability. Annual report Deliberately exiting less attractive revenue can make sense. The condition is that the retained portfolio eventually generates enough contribution to compensate for the lost sales and the cost of the change.

Project 420 therefore requires a careful distinction between a claimed savings run rate and completed integration. The annual MD&A says the US$33 million annualized synergy target was achieved during the fiscal year ended May 31, 2026, while the restructuring note says related initiatives are expected to be substantially completed by the end of fiscal 2027. Annual report, MD&A and Note 24 April 1, 2026 release, Project 420 Update Achieving a stated annualized target does not mean every closure, transition or cash cost has ended.

Carlsberg is another future operating test. The agreement entered on February 5, 2026 starts on January 1, 2027, has an initial five-year term and provides a further five-year renewal subject to performance criteria, according to the annual business description. Annual report It is a license to produce, market, sell and distribute specified brands in the United States. It is not revenue already earned merely because the contract was signed.

BrewDog’s September 28, 2026 announcement adds leadership in marketing, hospitality, category management and international commercial execution. Leadership announcement Those appointments establish responsibility, not improved results. Similarly, the September 22 campaign announcement attributes nearly £50 million of investment across operations, working capital, people and platform development to management. Campaign announcement That statement is not a separately audited new acquisition price, nor a cost entirely incurred after the fiscal-year balance-sheet date.

Brand promotions may support awareness, distribution and venue visits. They also consume resources and can reduce realized prices. Their economic success is assessed through repeat orders and contribution after marketing and fulfillment, rather than the publicity attached to a campaign. A future beverage improvement must be visible after those costs and under a consistent reporting perimeter.

08 Cash conversion and the working-capital burden

The subsequently filed August-quarter 10-Q reports $16.541 million of cash used in operations, compared with $1.341 million a year earlier. Cash, equivalents and restricted cash ended at $218.343 million, including $3.383 million restricted; another $3.047 million was in marketable securities. Quarterly report (Form 10-Q).

The annual cash-flow statement is the clearest test of whether reported activity financed itself. For the year ended May 31, 2026, operating activities used US$69.144 million, compared with US$94.599 million in the prior fiscal year. Annual report, cash-flow statement The improvement matters, but an improving outflow is still an outflow. Calling the company cash-generative requires a different result.

Management’s positive operating cash measure before working-capital movements was approximately US$18.2 million for the year ended May 31, 2026. Annual report, MD&A Removing working capital asks what the business would have produced before the cash effects of receivables, inventory and supplier payments. Those effects are part of operating the business, particularly after acquiring a platform whose customers pay later than the company incurs production and payroll costs.

The annual cash-flow statement for the year ended May 31, 2026 shows US$66.423 million absorbed by receivables, US$26.898 million by prepayments and other current assets and US$13.439 million by inventory, partly offset by US$19.401 million from payables and accrued liabilities. Annual report These movements are cash-flow changes, rather than simply the difference between two balance-sheet amounts. Acquisitions, currency and other non-cash movements can prevent the balance-sheet difference from matching them.

The MD&A attributes US$51.7 million of the year’s uncollected receivables and US$43.7 million of working-capital cash use to BrewDog for the year ended May 31, 2026; it also discusses customer terms of sixty to ninety days and amounts held in trust. Annual report These disclosures provide a plausible mechanism for temporary absorption. They do not guarantee timely collection or make the amounts immediately available to repay creditors.

At May 31, 2026, net receivables were US$189.170 million, including US$9.098 million in the table’s ninety-plus-day category, with an allowance of US$3.156 million. Annual report, Note 28 The aging category should not automatically be called overdue or uncollectible; contractual terms and the credit-loss estimate remain relevant. A useful future comparison would show collections, aging and new sales together, rather than celebrating a fall in receivables caused merely by lower activity.

Company-defined free cash flow was negative US$98.624 million for the year ended May 31, 2026, and negative US$45.764 million in the May quarter, using operating cash less net capital and intangible investment. Annual results, free-cash-flow reconciliation The annual measure excludes acquisition purchases from its definition. It therefore understates the total cash needed when the group is simultaneously buying businesses.

The annual financing section reports US$157.974 million of net share-issuance proceeds and US$130.994 million of net financing inflows for the year ended May 31, 2026. Annual report That funding explains how liquidity can remain substantial while operations and investing consume cash. The decisive future evidence is whether customer collections and ongoing contribution reduce the need for another financing cycle.

09 Liquidity, lease commitments and convertible debt

The July 24, 2026 sixth amendment to American Beverage Crafts Group’s Bank of America facility reduced revolving commitments from $25 million to $15 million and modified financial covenants. It also records a $10 million voluntary principal repayment made on May 29. This is a reduction in contractual revolving capacity, not a $15 million new cash inflow. Annual report (Form 10-K). Quarterly report (Form 10-Q).

Tilray held US$225.977 million of cash and equivalents, US$3.365 million of restricted cash and US$5.289 million of marketable securities at May 31, 2026. Annual report, balance sheet The unrestricted cash line is not identical to the US$234.631 million combined liquidity figure in the July 28 results materials. Annual results Restricted funds have conditions on use, while securities differ from cash even when their maturities are short.

The reported company-defined net debt was approximately US$0.7 million at May 31, 2026, in the July 28 announcement. Annual results This offsets selected debt balances against the stated liquidity aggregate and uses the convertible principal rather than only its discounted carrying amount. It does not mean there was no debt, and it does not include the full economic effect of every lease or operating commitment.

At May 31, 2026, the balance sheet reported US$8.775 million of bank indebtedness, US$138.585 million of long-term debt carrying value including its current portion and US$79.529 million of convertible-debenture carrying value. Annual report, Notes 13, 15 and 16 The convertible principal was US$88.0 million at that date; its lower carrying value reflects an unamortized discount rather than a smaller contractual principal. Annual report, Note 16

Lease liabilities totaled US$171.512 million at May 31, 2026, against US$71.866 million a year earlier; the latest total comprised US$46.725 million of operating leases and US$124.787 million of finance leases. Annual report, Note 7 Acquired hospitality and brewing operations help explain why fixed commitments grew. Lease liabilities are not an immediate demand for the entire balance, but future cash payments still compete with growth spending and debt service.

The undiscounted lease schedule at May 31, 2026 includes US$16.724 million of operating-lease payments and US$19.067 million of finance-lease payments for fiscal 2027. Annual report These payments are already reflected in the lease carrying value; they are not separate debt. The schedule illustrates timing and includes the effect of discounting and interest differently from the balance sheet.

The unsecured convertible notes mature on June 15, 2027 and bear 5.20% annual interest under the terms disclosed in the annual report. Annual report, Note 16 Subsequent exchanges reduced the reported principal to US$70.0 million by the July 28 filing date; the August 10 filing records a further US$6.0 million exchanged, and the September 14 filing records US$12.0 million exchanged in transactions through September 8, 2026. Annual report, subsequent events August filing September filing

Combining those disclosed amounts gives US$52.0 million after the identified transactions through September 8, 2026, calculated as US$70.0 million minus US$6.0 million minus US$12.0 million. Annual report; Merlintrader calculation August filing September filing The calculation updates the disclosed principal trajectory; it does not update May’s cash balance or establish that cash funded the exchanges.

10 Share issuance and the economics of debt exchanges

Equity financing can improve the company’s liquidity while reducing each existing shareholder’s percentage participation. For the year ended May 31, 2026, Tilray issued 19,625,505 shares through its ATM programs, generating US$161.636 million gross and US$157.974 million net proceeds, according to the annual equity note. Annual report, Note 18 The cash-flow benefit is real. So is the larger ownership denominator.

The ATM program entered on April 15, 2026 allowed up to US$180 million of sales, with annual MD&A reporting 12,848,281 shares issued under that new program by May 31, 2026. Annual report A program ceiling is not completed funding, and unissued capacity is not cash on the balance sheet. The annual disclosure also distinguishes this program from the earlier arrangement completed during the fiscal year.

At May 31, 2026, issued and outstanding common shares were 131,683,075, compared with 106,067,875 at May 31, 2025, on the annual report’s retrospectively adjusted basis. Annual report The September 28 definitive proxy records 147,782,141 voting shares outstanding at the September 24, 2026 record date. Definitive proxy The latter is the more recent official count, but it belongs to a particular record date rather than every subsequent trading session.

The August 10, 2026 filing reports issuance of 1,377,334 shares for US$6.0 million of convertible principal; the September 14 filing reports 2,841,650 shares for US$12.0 million of principal. August filing September filing These are debt-for-equity exchanges. They lower contractual debt and increase shares, without bringing in the cash that a public equity sale would raise. The debt reduction is not operating cash generation.

The exchange terms also differ from the note’s original conversion terms. Negotiated consideration reflects an agreement with holders and market conditions, so there is no assurance that every remaining note will convert under a single fixed relationship. Accrued interest, discounts and accounting gains require their own disclosures. A smaller debt balance can improve refinancing flexibility even when the transaction increases dilution.

Stock compensation is another part of the ownership equation. Expense was US$45.940 million for the year ended May 31, 2026, against US$24.289 million in the prior year; the annual report describes performance-award conditions established during the year and different equity or liability classifications. Annual report, Note 18 An add-back to adjusted EBITDA does not remove either the expense’s economic meaning or the potential settlement obligation.

The July 31, 2026 Form S-8 registers an additional 11,355,231 shares reserved under the incentive plan’s automatic increases. Incentive-plan registration Registration does not establish that those shares were issued on that day. Existing awards, plan reserves, actual vested shares and future financing capacity are distinct categories; treating them as one would exaggerate or understate dilution.

The ownership question is therefore broader than whether Tilray can fund another acquisition. It is whether the acquired profit and cash eventually grow faster than the share count, financing costs and fixed commitments. Business scale can rise without a comparable improvement in value attributable to each existing share.

11 US medical policy, hemp law and the MedMen option

US regulatory developments have different implications for medical cannabis, recreational cannabis and hemp-derived products. The April 28, 2026 federal rule addresses FDA-approved products containing marijuana and marijuana regulated under qualifying state medical frameworks; it is not a blanket federal authorization for adult-use sales. Federal medical rule Tilray’s operating permissions and route to market still require their own evidence.

The DEA’s September 29, 2026 stay and briefing order concerns the broader rescheduling proceeding and sets an October 13 response deadline. DEA order A procedural deadline is not a final merits decision. The timing should be tracked without converting a hearing window, submitted argument or administrative pause into an already completed broad rescheduling outcome.

The July 28, 2026 results release describes a medical-first US blueprint based on research, education, product development and compliant patient access. Annual results That is a management strategy. Existing pharmaceutical capabilities and patient-access platforms may be useful, but they do not establish US medical-cannabis revenue or a newly obtained federal commercial license. Projecting sales before these steps would substitute a market narrative for an operating disclosure.

Hemp rules introduce a different transition. Section 781 of Public Law 119-37, enacted November 12, 2025, changes the federal hemp definition with a delayed effective date originally set for November 12, 2026. Original hemp law However, Section 2019 of Public Law 119-103, enacted September 2, 2026, limits application until December 11, 2026 to specified intermediate and final products containing cannabinoids the plant cannot naturally produce. September law The current position is not an unchanged blanket November ban on all hemp-derived drinks.

The September provision does not repeal the amended definition or guarantee that every product remains compliant. Product formulation, state law and the later federal timetable matter. Tilray’s annual comments about reducing hemp-derived beverage activity predate that legislative change; the law alone does not prove that management restarted a discontinued product line. Ordinary hemp-seed foods also have a different composition and regulatory exposure from intoxicating cannabinoid beverages.

The former MedMen investment needs equally careful wording. The annual report states that the old convertible note was disposed of in exchange for an option to acquire a 68% membership interest in SH Acquisition for US$1 upon US federal cannabis legalization; the option’s carrying value at May 31, 2026 was US$4.364 million, against US$8.160 million a year earlier. Annual report, Notes 11, 20 and 28 This is an option contingent on a legal condition, not current ownership of a functioning national dispensary chain.

The annual valuation discussion says projected retail-operation cash flows used for that option were reduced to nil, leaving projected brand-related cash flows in the model at May 31, 2026. Annual report That statement explains the accounting value’s basis; it does not say the brands will necessarily earn that cash. Regulatory optionality remains uncertain and should be evaluated separately from businesses already producing reported revenue.

12 Governance, controls and legal exposure

Three Form 4s report open-market purchases: Carl Merton bought 10,000 shares at $4.62 on August 4, Denise Faltischek bought 2,500 at $4.78 on August 3, and Mitchell Gendel bought 2,500 at $4.43 on August 6. Irwin Simon’s August 26 entries instead reflect performance-award vesting and shares withheld for taxes. These are different transaction types, and the purchases are not evidence of future operating performance. SEC ownership filing. SEC ownership filing. SEC ownership filing. SEC ownership filing.

The definitive proxy dated September 28, 2026 schedules the shareholder meeting for November 18, 2026 at 11:00 a.m. Eastern Standard Time. Definitive proxy Its substantive governance proposal would declassify the board and permit director removal without cause under the proposed framework. It is a proposal, not a reform already implemented.

The proposal requires approval by at least two-thirds of outstanding shares entitled to vote; the proxy notes that comparable proposals failed to obtain the necessary support at the prior annual meetings. Definitive proxy, Governance Proposal The approval threshold matters because absence or non-voting can have a different practical effect from an affirmative vote. If approved and the amendment is filed, the proxy says all directors would stand for election at the annual meeting in 2027. Definitive proxy

Compensation deserves attention because equity awards connect operating metrics to the ownership denominator. The proxy’s fiscal 2026 summary table reports US$22.157 million of total compensation for the chief executive, including US$18.817 million of stock-award grant-date value. Definitive proxy, compensation table Grant-date accounting value is not the same as cash received or proceeds from selling vested stock. Criticism or praise should use the actual category rather than combining them.

The September 28, 2026 proxy also describes August settlement decisions using both shares and cash for specified performance awards. Definitive proxy This updates the annual report’s expectation concerning settlement and means the award program is not exclusively non-cash. A reasonable assessment considers performance conditions, cash needs, dilution and the relationship between compensation and outcomes belonging to shareholders.

Disclosure controls and internal control over financial reporting were assessed as effective at May 31, 2026, with an unqualified audit opinion in the annual report. Annual report, auditor’s report and Item 9A However, newly acquired BrewDog operations and Lyphe were excluded from management’s first-year internal-control assessment under the permitted acquisition treatment. Annual report The conclusion therefore should not be enlarged into a separate assurance that every recently acquired control system had already undergone the same assessment.

Legal exposure is not equivalent to a recorded liability. The annual report describes the MMIRF complaint seeking damages in excess of US$1 billion, while stating at the July 28, 2026 filing date that management did not regard a loss as probable or reasonably estimable. Annual report, Note 27 The requested amount belongs to a plaintiff’s claim, not an adjudicated debt or a company admission. Existing litigation provisions are not a guaranteed ceiling on every possible outcome.

The same annual note reports a June 25, 2026 German court judgment in Tilray’s favor in the Fotmer dispute, alongside continuing enforcement considerations. Annual report A favorable judgment is different from cash already collected. Governance, litigation and controls affect the quality of the operating transition; their disclosed status reflects the date of each specific document.

13 What the next reporting cycle needs to establish

Management’s July 28, 2026 guidance is adjusted EBITDA of US$68 million to US$75 million for the fiscal year ending May 31, 2027; the chief executive also expresses an expectation of revenue above US$1 billion. Annual results These are forward-looking management statements. They are not reported results, and adjusted EBITDA guidance is not a forecast of unrestricted cash.

The results for the quarter ended August 31, 2026 were released on October 8, 2026. Results release The useful questions extend beyond whether consolidated sales rise. They include the acquired revenue contribution, performance of the pre-acquisition beverage portfolio, international cannabis pricing, distribution margin and the point at which working-capital investment starts returning cash.

Receivable collections are best read together with sales and aging. A release of acquisition-related working capital could improve cash substantially without proving that every business has become structurally profitable. Conversely, one seasonal inventory build need not invalidate an otherwise improving model. Consistency over reporting periods, with an explanation of scope changes, is more informative than selecting the most favorable adjusted subtotal.

Finviz data as of September 30, 2026 show a reference price of US$3.75, market capitalization of US$554.18 million, a share count of 147.78 million, short float of 13.44% and institutional ownership of 9.70%. Finviz market data These fields reflect Finviz’s market snapshot on the stated date. They do not independently prove a live shareholder register, an active short seller’s motive or future squeeze potential.

Short interest can influence market behavior around events, but the quoted fraction should not become a forecast. Institutional ownership does not demonstrate professional endorsement of the thesis, and daily price moves do not supply a reason for the move without separate evidence. No unattributed analyst target, social consensus or passive-index flow assumption is needed to explain this company.

The editorial Health Score is a structured assessment of resources, catalysts, capital discipline, trading liquidity and operating execution. Its strengths rest on cash and a broad operating platform; its limitations rest on negative actual operating cash, acquisition integration, dilution and the difference between regulatory possibilities and completed commercial permissions. It is not a valuation model or a recommendation.

A convincing improvement would show acquired and existing operations generating a greater contribution with less incremental funding. A weaker outcome would show purchased scale continuing to absorb cash while the share count grows. Those are evidence-based operating conditions to evaluate, with the next filings providing the necessary detail; neither condition promises a particular share-price outcome.

First-quarter fiscal 2027 results, released on October 8, 2026. For the quarter ended August 31, 2026 net revenue rose 23% to $257.1 million from $209.5 million and gross profit rose 35% to $77.5 million, with gross margin at 30% against 27%. By segment, beverage revenue increased 82% to $101.5 million, reflecting the BrewDog acquisition, with a 41% gross margin; cannabis revenue was $56.1 million against $64.5 million, with gross margin up to 39% from 36%; distribution revenue increased 14% to $84.3 million at an unchanged 11% margin; wellness revenue was flat at $15.3 million. The net loss was $40.0 million, or $0.32 per share, which the company attributes predominantly to non-cash charges; the adjusted net loss was $3.0 million, or $0.02 per share, and adjusted EBITDA was $9.2 million against $10.2 million, burdened by about $1.7 million of fuel surcharges. Cash, restricted cash and marketable securities, a non-GAAP measure, totalled $221.4 million, total debt was reduced by $42 million fiscal year to date, and the company reported a net cash position on its own non-GAAP definition. Guidance for adjusted EBITDA of $68 million to $75 million for the year ending May 31, 2027 was reaffirmed, with results historically weighted toward the second half. Results release (SEC Exhibit 99.1)

Read against the questions this page sets, the quarter confirms the acquired beverage contribution and a lower cannabis revenue line, while adjusted figures and a reaffirmed guidance range are not a measure of spendable cash. The quarter’s Form 10-Q is now available: it reports $16.541 million of operating cash outflow. The next test is improvement in cash conversion, using the filed cash-flow and working-capital detail. Quarterly report (Form 10-Q).